SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Shapiro who wrote (412)10/1/1998 10:34:00 AM
From: Gerald Underwood  Read Replies (1) of 857
 
Au Contraire,

This type of immediate and coherent action is needed to assure shareholders that their company and capitol assets are being defended against this type of thing. No one wants to feel that they are subject to a downdraft in their holdings due to anything an analyst wants to say about them, founded or unfounded. Analyst's have to be held responsible for direct accusations and unfounded statements that may drastically affect the stock price and the stockholders need to be aware that this action is being taken without delay.

As for scrutiny, any company is aware that they will be subjected to more scrutiny in a lawsuit. This indicates to me that they are willing to and believe that additional exposure will vindicate them.

IMO, in view of the allegations made against HEB, such reaction is definitely called for.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News